BREEN EDWARD D sold $13.2M of DD

BREEN EDWARD D sold 89,845 shares of DuPont de Nemours, Inc. (DD) at $146.41 ($13.15M total) on 2026-11-05.

Original reporting
SEC EDGAR · BREEN EDWARD D
Published Nov 9, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DD
Bearish
high confidence
Mentioned
$DD
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DDBearishMed
01

Why it matters

The $13.2M sale by a director may trigger short‑term selling pressure, but the retained stake suggests continued confidence.

02

Market read

First‑report insider sale of material size; traders may consider short‑term downside risk.

03

What to watch

The director retains 127,276 shares, still a sizable stake, and the sale was pre‑arranged under a 10b5‑1 plan is false, indicating no urgency.

Relevance 6/10Novelty 7/10Timing: post‑market today

Background

SEC Form 4 filings disclose insider transactions; investors monitor them for potential signals about company outlook.

Company-level read

Ticker impact

$DDBearishHigh confidence
Context

Director Breen Edward D sold 89,845 DD shares for $13.2M on 5 Nov 2026.

Expected impact

downward pressure as the market prices in the insider sell.

Evidence & confidence

The sale represents a $13M disposition by a senior insider, a material amount for a mid‑cap stock, and is disclosed for the first time via a Form 4.

Market effects

Limited; the sale is company‑specific and does not materially affect the chemicals sector.

Minimal impact on U.S. markets beyond DD.

Low; the filing is a routine insider transaction.

Counterpoint

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • DuPont de Nemours, Inc.

    Chemical conglomerate listed on NYSE under ticker DD.

  • Breen Edward D

    Director of DuPont who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DDMed

Wells Fargo raises DuPont stock price target to $170 on valuation

Wells Fargo raised its price target for DuPont (NYSE:DD) to $170 from $166, maintaining an Overweight rating. The firm cites a higher-quality portfolio and a 2027 EV/EBITDA multiple of 13x. DuPont reported Q3 earnings of $2.09 per share on $1.9B revenue, a 4% increase. UBS also raised its target to $182, citing margin strength. Shares trade at $150.73, with potential upside to $170.

$DDHighAI 9/10

What Just Happened To DuPont Stock?

DuPont (DD) stock rose 8.6% on November 3, 2026, after reporting Q3 2026 earnings of $2.09 per share, beating estimates of $1.87. Sales reached $1.9B, up 4% YoY. The company raised its full-year guidance to $7.50 EPS and $7.19B in sales. Management cited strong order growth but delayed some Middle East projects to 2027. Most peers fell, with only Celanese rising 5.0%.

$DDHighAI 9/10

DuPont de Nemours Q3 Earnings Call Highlights

DuPont (NYSE: DD) reported Q3 Diversified Industrials operating EBITDA up 11% to $242M, with a 24.1% margin. The company highlighted productivity gains, AI initiatives, and raised its 2026 outlook to $7.19B in net sales and $1.785B in EBITDA. Q4 projections include $1.825B in net sales and $455M in EBITDA. DuPont also announced share repurchases and M&A plans.